• Home
  • > Media & Investors
  • > Investor Relations
  • > IR Calendar
  • > Lancet Oncology Publications of Phase 1 Dose Expansion Results of DS-8201 in HER2 Positive Metastatic Breast and Gastric Cancer

Lancet Oncology Publications of Phase 1 Dose Expansion Results of DS-8201 in HER2 Positive Metastatic Breast and Gastric Cancer

Tuesday, May 07, 2019

Daiichi Sankyo Announces Two Lancet Oncology Publications of Phase 1 Dose Expansion Results of [Fam-] Trastuzumab Deruxtecan in HER2 Positive Metastatic Breast and Gastric Cancer

• 20.7 months median duration of response achieved in patients with HER2 positive metastatic breast cancer previously treated with T-DM1
• 7.0 months median duration of response achieved in patients with HER2 positive metastatic gastric cancer previously treated with trastuzumab

• Tamura K, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1study. Lancet Oncol 2019. April 29, 2019. http://dx.doi.org/10.1016/S1470-2045(19)30097-X.
• Shitara K, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol 2019. April 29, 2019. http://dx.doi.org/10.1016/S1470-2045(19)30088-9.

Related Data

In order to view the PDF files, you need to have the latest version of Adobe Reader installed.